- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 11th, 2007
Piper Jaffray initiates coverage on Nanosphere (Nasdaq: NSPH) with a Buy rating and a $17 price target.
The firm said Nanosphere's core technology is solid and its recent FDA approval for its Verigene molecular diagnostics instrument will lead to long-term revenue growth.
|Related News Press|
FEI Company: Strong Growth Prospects Remain May 1st, 2015
Arrowhead to Present at Upcoming Conferences April 28th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
New Nanodrug Produced in Iran from Milk Thistle May 4th, 2015
Polymeric Nanocarriers Improve Performance of Anticancer Drugs April 30th, 2015
Defects in atomically thin semiconductor emit single photons: Researchers create optically active quantum dots in 2-D semiconductor for the first time; may have applications for integrated photonics May 4th, 2015